Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Halozyme Therapeutics missed estimated earnings by 4.08%, reporting an EPS of $0.47 versus an estimate of $0.49.
Revenue was up $28.26 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.01 which was followed by a 2.9% increase in the share price the next day.
Here's a look at Halozyme Therapeutics's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.41 | 0.42 | 0.40 | 0.32 |
| EPS Actual | 0.42 | 0.55 | 0.66 | 0.37 |
| Revenue Estimate | 100.32M | 101.94M | 103.16M | 84.88M |
| Revenue Actual | 102.00M | 115.83M | 136.46M | 89.02M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Halozyme Therapeutics management provided guidance for FY 2022, expecting earnings between $2.05 and $2.2 per share.
To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
